GHRP-2 (5 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency is once daily by subcutaneous injection for the whole course. This once-daily schedule balances efficacy with receptor recovery time and avoids the rapid attenuation seen with frequent dosing, and administering in the evening may capitalize on nocturnal GH rhythms. At 5 mg/mL every dose in this protocol falls between 2 and 6 units, which is well under the 10 unit (0.10 mL) threshold where readability starts to matter, so a 30 unit or 50 unit insulin syringe is the sensible barrel here rather than a 100 unit one. Sites are rotated systematically across abdomen, thighs, and upper arms to reduce local irritation and prevent lipodystrophy.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: titration at 100 mcg daily, 2 units per injection, establishing tolerance and a consistent injection routine.
• Weeks 3 to 4: step up to 150 mcg daily, 3 units per injection.
• Weeks 5 to 8: maintenance at 200 mcg daily, 4 units per injection. This is where the standard 8 week course ends.
• Weeks 9 to 12: maintenance held at 200 mcg daily for anyone running the longer 12 week course.
• Weeks 13 to 16: optional extension, still at 200 mcg daily, with the same once daily cadence throughout.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl or roll until completely dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light, and use within 2 to 3 weeks. At 5 mg/mL, 1 unit = 0.01 mL » 50 mcg on a U-100 insulin syringe, so 100 mcg is 2 units, 150 mcg is 3 units, and 200 mcg is 4 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C in dry, dark conditions. The powder is stable at room temperature for short periods, but freezer storage maximizes shelf life.
• Reconstituted: refrigerate at 2 to 8 °C and use within 2 to 3 weeks for optimal integrity.

• For longer storage, consider aliquoting and freezing at minus 20 °C with carrier protein, and avoid repeated freeze-thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake, and always protect from light and heat.

Supplies Needed

Planning math is based on the 8 to 16 week daily protocol with gradual titration, which averages about 1.4 mg per week once the 200 mcg maintenance dose is reached.

Peptide Vials (GHRP-2, 5 mg vial):

• A 12 week course totals about 14.7 mg of GHRP-2, and the master sheet plans about 4 vials of 5 mg for it because a reconstituted vial is discarded after 2 to 3 weeks; an 8 week course totals about 9.1 mg and about 2 vials, and a 16 week course totals about 20.3 mg and about 5 vials.

Insulin Syringes (U-100):

• Per week: 7 U-100 insulin syringes, one per day, with a 30 unit or 50 unit barrel preferred at these small volumes.
• Full cycle: 56 syringes at 8 weeks, 84 at 12 weeks, and 112 at 16 weeks.

Bacteriostatic Water (10 mL bottles):

• At 1.0 mL of bacteriostatic water per 5 mg vial, one 10 mL bottle covers 10 vials, so a single bottle covers the full 16 week course.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin, which is 14 per week.
• Full cycle: 112 swabs at 8 weeks, 168 at 12 weeks, and 224 at 16 weeks, which is three boxes of 100.

Important Notes

Practical considerations for consistency and safety.

• Use a new sterile insulin syringe for each injection and dispose of it in a sharps container.
• Rotate injection sites across abdomen, thighs, and upper arms to reduce local irritation and prevent lipodystrophy.
• Very frequent dosing, for example every 2 hours, can cause progressive attenuation due to acute tachyphylaxis. Once daily administration avoids this issue. Multiple daily injections of 2 to 3 times per day have been explored, but they require strict adherence and may offer limited added benefit.
• At 5 mg/mL a single vial holds 100 units of solution, which is 25 days at the 200 mcg maintenance dose. That runs past the 2 to 3 week window for reconstituted material, so some residual peptide is discarded rather than carried on, and the vial count above already allows for it.
• Document the daily dose and site rotation to maintain consistency across the course.
• Regulatory Note: GHRP-2 is not an approved drug for human therapeutic use and is supplied for research purposes only, not for human consumption. The master sheet does not record a WADA classification for this compound.

How This Works

GHRP-2 is a synthetic growth hormone secretagogue that binds to and activates ghrelin (GH secretagogue) receptors. That activation triggers potent, pulsatile release of growth hormone from the pituitary gland in a dose-dependent manner. Clinical studies in GH-deficient children demonstrated meaningful GH increases even at low doses of 0.3 to 3.0 mcg/kg, with escalating doses over several months showing sustained efficacy. In healthy adults, doses of 100 mcg subcutaneously per day produce acute GH stimulation, while routine protocols typically maintain 100 to 300 mcg per day to balance efficacy with receptor sensitivity. The peptide has been well tolerated in clinical trials, with no significant adverse effects or toxicity reported at these dosage ranges.

Benefits & Side Effects

Observations from the published record.

• Stimulates robust pulsatile GH release that may support favorable body composition changes and metabolic effects.
• In combination therapies, for example with GHRH analogs, can significantly increase IGF-1 levels when administered with perfect compliance.
• Long-term therapy of 8 to 24 months in GH-deficient subjects has maintained positive effects on growth velocity with careful monitoring.
• Generally well tolerated with a placebo-like safety profile. Transient side effects may include mild hunger sensation or flushing.
• Occasional mild injection-site reactions such as redness and irritation may occur with subcutaneous administration.
• Five day dosing studies in healthy young men recorded response attenuation with daily subcutaneous use, which is part of why the once daily cadence and the titration steps above are kept conservative.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain adequate protein intake and balanced nutrition to support the anabolic effects of elevated GH.
• Combine with resistance training to maximize body composition benefits.
• Prioritize sleep quality, since GH pulses naturally occur during deep sleep and evening administration may complement that rhythm.
• Manage stress effectively and stay well hydrated to support consistent adherence, recovery, and metabolic processes.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Effects of GHRP-2 on GH release and growth performance (Domestic Animal Endocrinology).
2. Effects of eight months treatment with graded doses of GHRP-2 in GH-deficient children (J Clin Endocrinol Metab).
3. Five-day treatment with daily subcutaneous GHRP-2: response attenuation and IGF-I effects in healthy young men (Eur J Endocrinol).
4. GH/IGF-1 response to acute and chronic GHRP-2, GHRH 1-44, and their combination in older adults (Endocrine).